Physician profile
Michael Krabak
NPI 1578557302
$9,157.31
in general payments reported to CMS, 2019-2025
34 companies · $2,015 in 2025
The $2,015 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,298 · 2020: $1,486 · 2021: $1,290 · 2022: $28.43 · 2023: $667 · 2024: $374 · 2025: $2,015.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,770 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,770.42 |
| Education | $284.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $5,012.12 | 2019-2025 | Ninlaro |
| Incyte Corporation | $480.06 | 2020-2025 | Monjuvi, Jakafi, Niktimvo |
| Abbvie INC. | $427.57 | 2021-2025 | |
| Lilly USA, LLC | $380.10 | 2019-2025 | Verzenio, Retevmo |
| Novartis Pharmaceuticals Corporation | $297.33 | 2023-2025 | |
| Genzyme Corporation | $292.32 | 2019-2025 | |
| Amgen INC. | $225.99 | 2020 | |
| Pfizer INC. | $223.20 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $205.68 | 2019-2025 | Reblozyl |
| Glaxosmithkline, LLC. | $193.24 | 2023-2025 | Ojjaara, Blenrep |
| Seagen INC. | $192.94 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $178.82 | 2019-2025 | Tagrisso |
| Medtronic, INC. | $160.94 | 2025 | Synchromedii |
| Astellas Pharma US INC | $122.06 | 2019-2025 | Xtandi |
| Syndax Pharmaceuticals, INC. | $120.22 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $84.15 | 2022-2025 | Reblozyl |
| Janssen Biotech, INC. | $72.63 | 2024-2025 | Rybrevant, Darzalex |
| Pharmaessentia USA Corporation | $57.02 | 2023 | Besremi |
| Merck Sharp & Dohme LLC | $55.55 | 2024-2025 | Keytruda, Lynparza |
| Pharmacosmos Therapeutics INC. | $52.10 | 2025 | Monoferric |
| Genentech USA, INC. | $48.86 | 2025 | Tecentriq, Itovebi |
| Sobi, INC | $38.49 | 2024-2025 | |
| Array Biopharma INC | $35.19 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Bayer Healthcare Pharmaceuticals INC. | $31.42 | 2024 | |
| Shield Therapeutics INC | $21.11 | 2025 | |
| Daiichi Sankyo INC. | $19.49 | 2024 | Enhertu |
| Stemline Therapeutics INC. | $19.00 | 2025 | Orserdu |
| Beigene USA, INC. | $18.41 | 2025 | Brukinsa |
| Beone Medicines USA, INC. | $18.22 | 2025 | Tevimbra |
| Taiho Oncology, INC. | $17.88 | 2025 | |
| Alnylam Pharmaceuticals INC. | $15.97 | 2025 | Onpattro |
| Adaptive Biotechnologies Corporation | $13.94 | 2025 | Clonoseq |
| Eisai INC. | $13.37 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Krabak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.